Nov 25, 2011 · The strain Escherichia coli Nissle 1917 (EcN) is widely used as an efficient probiotic in therapy and prevention of human infectious diseases, especially of the intestinal system. Concurrently, small adult pigs are being used as experimental omnivore models to study human gastrointestinal functions. EcN bacteria were applied to 6 adult healthy female pigs in a 2-week trial. 6 Control animals
Jun 6, 2022 · Escherichia coli NISSLE 1917 (EcN) is a Gram-negative strain with many prominent probiotic properties in the treatment of intestinal diseases such as diarrhea and inflammatory bowel disease (IBD), in particular ulcerative colitis. EcN not only exhibits antagonistic effects on a variety of int …
Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and IBD, in particular UC. For Research Use Only.
May 6, 2022 · Compared with other probiotics, Escherichia coli Nissle 1917 (EcN) is a well-established bacterium for genetic modification (Rembacken et al., 1999; Kruis, 2004; Coqueiro et al., 2019). Thus, EcN meets all requirements for a therapeutic agent and is well recognized as a safe probiotic for human use.
Nov 9, 2022 · Nattokinase with excellent anti-thrombotic, anti-inflammatory, anti-tumor, and anti-hypertension properties has been used in the development of several healthcare products in many countries. The probiotic Escherichia coli Nissle 1917 (EcN) with anti-inflammatory effect is commonly used to treat inflammatory bowel disease. To determine whether nattokinase could enhance the therapeutic efficacy Escherichia coli strain Nissle 1917 (EcN) has been used as a probiotic. Genetic engineering has enhanced the utility of EcN in several vaccine and pharmaceutical prepara-tions. We discuss in this mini review the genetics and physical properties of EcN. We also discuss the numerous genetic en-gineering strategies employed for EcN-based vaccine
. 2702451810028841831044
